Abstract
Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor-based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enable patients to continue effective treatment while maintaining good quality of life.
Trial registration:
ClinicalTrials.gov NCT00678769 NCT01378377 NCT01529593.
Publication types
-
Clinical Trial, Phase I
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Female
-
Humans
-
Male
-
Metformin / therapeutic use
-
Middle Aged
-
Mucositis / chemically induced
-
Mucositis / epidemiology*
-
Niacinamide / analogs & derivatives
-
Niacinamide / therapeutic use
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use
-
Retrospective Studies
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Treatment Outcome
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
-
Protein Kinase Inhibitors
-
cixutumumab
-
Niacinamide
-
temsirolimus
-
Metformin
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus
Associated data
-
ClinicalTrials.gov/NCT00678769
-
ClinicalTrials.gov/NCT01378377
-
ClinicalTrials.gov/NCT01529593